• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Refining clinical decision strategies and prostate cancer detection through fine adjustments in the combination of PSA-derived parameters and MRI.

作者信息

Muglia Valdair Francisco

机构信息

Department of Medical Images, Oncology and Hematology, Ribeirao Preto School of Medicine, University of Sao Paulo (USP), Sao Paulo, Brazil.

出版信息

Eur Radiol. 2024 Oct;34(10):6227-6228. doi: 10.1007/s00330-024-10734-3. Epub 2024 Apr 29.

DOI:10.1007/s00330-024-10734-3
PMID:38683387
Abstract
摘要

相似文献

1
Refining clinical decision strategies and prostate cancer detection through fine adjustments in the combination of PSA-derived parameters and MRI.通过对前列腺特异性抗原（PSA）衍生参数与磁共振成像（MRI）组合进行微调来优化临床决策策略和前列腺癌检测。
Eur Radiol. 2024 Oct;34(10):6227-6228. doi: 10.1007/s00330-024-10734-3. Epub 2024 Apr 29.
2
Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies.双参数磁共振成像（MRI）作为无既往活检史男性基于前列腺特异性抗原（PSA）检测前列腺癌的辅助手段的诊断价值。
BJU Int. 2015 Mar;115(3):381-8. doi: 10.1111/bju.12639. Epub 2014 Sep 15.
3
Development and validation of risk-stratified biopsy decision pathways incorporating MRI and PSA-derived indicators.纳入MRI和PSA衍生指标的风险分层活检决策路径的开发与验证
Ann Med. 2025 Dec;57(1):2446695. doi: 10.1080/07853890.2024.2446695. Epub 2025 Jan 1.
4
Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.联合临床参数和多参数磁共振成像进行前列腺癌高危风险建模-个体化风险分层可减少不必要的活检。
Eur Urol. 2017 Dec;72(6):888-896. doi: 10.1016/j.eururo.2017.03.039. Epub 2017 Apr 8.
5
Magnetic Resonance Imaging-based Prostate Cancer Screening in Carriers of Pathogenic Germline Mutations: Interim Results from the Initial Screening Round of the Prostate Cancer Genetic Risk Evaluation and Screening Study.基于磁共振成像的致病性种系突变携带者前列腺癌筛查：前列腺癌遗传风险评估与筛查研究首轮筛查的中期结果。
Eur Urol Oncol. 2024 Dec;7(6):1358-1366. doi: 10.1016/j.euo.2024.01.015. Epub 2024 Mar 6.
6
Development and validation of a clinical decision support system based on PSA, microRNAs, and MRI for the detection of prostate cancer.基于前列腺特异性抗原（PSA）、微小RNA（microRNAs）和磁共振成像（MRI）的前列腺癌检测临床决策支持系统的开发与验证
Eur Radiol. 2024 Aug;34(8):5108-5117. doi: 10.1007/s00330-023-10542-1. Epub 2024 Jan 4.
7
Implementation of multiparametric magnetic resonance imaging technology for evaluation of patients with suspicion for prostate cancer in the clinical practice setting.在临床实践环境中，实施多参数磁共振成像技术对疑似前列腺癌患者进行评估。
BJU Int. 2019 Feb;123(2):239-245. doi: 10.1111/bju.14515. Epub 2018 Sep 14.
8
Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.前列腺影像报告和数据系统（PI-RADS）评分与前列腺特异性抗原（PSA）密度相结合可预测初次接受前列腺穿刺活检患者的活检结果。
BJU Int. 2017 Feb;119(2):225-233. doi: 10.1111/bju.13465. Epub 2016 Apr 1.
9
Usefulness of MRI targeted prostate biopsy for detecting clinically significant prostate cancer in men with low prostate-specific antigen levels.磁共振成像引导下靶向前列腺穿刺活检在低前列腺特异性抗原水平男性中诊断临床显著前列腺癌的价值。
Sci Rep. 2021 Nov 9;11(1):21951. doi: 10.1038/s41598-021-00548-4.
10
Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population.PRIMA 试验结果：在未经活检的人群中，比较 STHLM3 试验和前列腺特异性抗原在一般实践中的前列腺癌检测。
Eur Urol Oncol. 2023 Oct;6(5):484-492. doi: 10.1016/j.euo.2023.07.006. Epub 2023 Aug 1.

本文引用的文献

1
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.EAU-EANM-ESTRO-ESUR-SIOG 前列腺癌指南-2020 版更新。第 1 部分：筛查、诊断和以治愈为目的的局部治疗。
Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7.
2
Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation.在首次前列腺癌诊断评估中，基于前列腺磁共振成像和前列腺特异性抗原密度进行风险适应性活检决策，以增强活检避免率。
BJU Int. 2021 Feb;127(2):175-178. doi: 10.1111/bju.15277. Epub 2020 Nov 13.
3
Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
基于前列腺磁共振成像结局数据库（PROMOD）的多中心回顾性研究：应用前列腺特异性抗原密度和磁共振成像联合进行前列腺活检决策规划
Eur Urol Oncol. 2021 Dec;4(6):971-979. doi: 10.1016/j.euo.2020.08.014. Epub 2020 Sep 21.
4
Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection.PI-RADS v2.1对前列腺癌检测的前瞻性评估
AJR Am J Roentgenol. 2020 Nov;215(5):1098-1103. doi: 10.2214/AJR.19.22679. Epub 2020 Sep 2.
5
False positives in PIRADS (V2) 3, 4, and 5 lesions: relationship with reader experience and zonal location.PI-RADS（版本 2）3、4、5 级病变中的假阳性：与读者经验和区域位置的关系。
Abdom Radiol (NY). 2019 Mar;44(3):1044-1051. doi: 10.1007/s00261-019-01919-2.
6
Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.前列腺影像报告和数据系统（PI-RADS）评分与前列腺特异性抗原（PSA）密度相结合可预测初次接受前列腺穿刺活检患者的活检结果。
BJU Int. 2017 Feb;119(2):225-233. doi: 10.1111/bju.13465. Epub 2016 Apr 1.